Skip to main content
Premium Trial:

Request an Annual Quote

ChondroGene Pens Molecular Dx Alliance With Two Malaysian Hospitals

NEW YORK, June 10 (GenomeWeb News) - ChondroGene has partnered with a pair of hospitals in Malaysia to develop a suite of molecular diagnostics for certain diseases based on its Sentinel Principle technology, the company said today.


As part of the alliance, Lam Wah EE Hospital and IslandHospital, located in Penang, will provide ChondroGene with blood samples from patients with cancer, cardiovascular disease, central nervous system disorders, and arthritis, the company said.


ChondroGene, based in Toronto, will use genetic data extracted from these samples to help it identify blood-based biomarkers for specific diseases in these areas. ChondroGene will also add the data to its database of gene-expression profiles, which the firm said currently contains profiles from controls and "several thousand people possessing a wide range of disease conditions."


The hospitals said they would offer ChondroGene's tests to their patients as the diagnostics become available.

K. Wayne Marshall, president and CEO of ChondroGene, said he "expect[s] to enter into similar relationships with other organizations around the world in the future in order to further expand the genetic diversity of our gene expression database. ..."

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.